Related Experiment Videos
Recent advances in validating MDM2 as a cancer target
Elizabeth R Rayburn1, Scharri J Ezell, Ruiwen Zhang
1Department of Pharmacology and Toxicology, Division of Clinical Pharmacology, University of Alabama at Birmingham, Birmingham, AL 35294-0019, USA.
Anti-Cancer Agents in Medicinal Chemistry
|June 23, 2009
Summary
The MDM2 oncogene, implicated in cancer, interacts with tumor suppressor p53. New therapies targeting this interaction and MDM2
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- MDM2 oncogene overexpression is linked to aggressive, treatment-resistant human cancers.
- The MDM2-p53 regulatory loop is a key target for cancer therapeutics.
- MDM2 exhibits p53-independent oncogenic roles, complicating targeted therapy.
Purpose of the Study:
- To explore the complex regulation of the MDM2-p53 interaction.
- To identify novel therapeutic strategies targeting MDM2 and its regulators.
- To understand the clinical implications of MDM2-p53 pathway modulation.
Main Methods:
- Utilizing high-throughput screening to discover small molecule inhibitors.
- Synthesizing inhibitors based on MDM2-p53 complex crystal structures.
- Investigating the role of regulatory proteins in the MDM2-p53 interaction.
Main Results:
- Specific and effective inhibitors of the MDM2-p53 protein-protein interaction were identified.
- Evidence suggests MDM2 possesses oncogenic functions independent of p53.
- Multiple proteins are involved in regulating the MDM2-p53 interaction.
Conclusions:
- A deeper understanding of MDM2 regulation is crucial for clinical translation of MDM2 inhibitors.
- Targeting MDM2, its regulators, or combining therapies may enhance tumor eradication.
- Elucidating specific regulatory interactions is key to optimizing cancer treatment strategies.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:15M-Cdk Drives Transition Into Mitosis
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
02:23Abnormal Proliferation
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...